CClinicalTrials.gg
CompletedNCT04529993DISCOVAIRUpdated Mar 24, 2025

An Atlas of Airways at a Single Cell Level in Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Controls

An interventional study of Bronchoscopy in Pulmonary Disease, Chronic Obstructive and Interstitial Pulmonary Fibrosis, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The increasing incidence of chronic respiratory disease is a public health problem that affects hundreds of thousands of people worldwide at all ages. Directly exposed to atmospheric airborne contaminants (pollution, allergens), the respiratory tract represents a complex ecosystem involving different cells (multiciliated, basal, mucosecretory, neuroendocrine, etc.) that develop complex interactions with the surrounding connective tissue but also with their rich immune environment and the local microbiota. Although a pathophysiological continuum is postulated between the nasal and bronchial airways in certain diseases, such as allergic diseases, investigators have demonstrated large gene expression gradients between samples taken from the nasal and bronchial airways in different studies. Specifying the cellular variability throughout the respiratory tree in a normal physiological situation is one of the major objectives defined in the establishment of an atlas of all airway cells, as defined in the objectives of the international consortium Human Cell Atlas.

The sequencing of the RNAs present specifically in each individual cell ("single-cell RNAseq"), and its comparison with neighbouring cells allows to document the precise cellular contributions, as well as the signalling pathways involved. The development of tissue sampling, stabilization, transport and single cell analysis procedures can be performed on primary respiratory epithelium cultures and can also be extended to respiratory samples from healthy volunteers.

This project will analyze gene expression profiles at the single cell level (single cell RNAseq) in volunteers with chronic obstructive pulmonary disease, interstitial pulmonary fibrosis and compared to healthy subjects of the same age. The technical modalities of the samples will be brushing and staged airway biopsies for direct analysis of the samples. This approach will be complemented by an air-liquid interface culture to allow secondary analysis in single cell RNAseq and three-dimensional mapping of the distribution of these cells with single cell in situ analysis.

Thanks to sampling at several levels of the respiratory tree (nose, bronchioles, bronchioles), cellular and gene expression variations along the tracheobronchial axis will be exhaustively documented in subjects of different ages, healthy or suffering from pathologies such as chronic obstructive pulmonary disease and interstitial pulmonary fibrosis. These data will serve as worldwide references for comparisons in different physiological and pathological contexts.

02

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
  • Interstitial Pulmonary Fibrosis

Keywords

  • lung
  • nasal mucosa
  • respiratory mucosa
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 71 is close to the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Absence of acute pathology
  • Absence of symptom evoking an evolutionary pathology

For healthy volunteers :

  • Non-smoker (active or passive) or ex-smoker of less than 5 packet-years and quit for more than 10 years.
  • Absence of known significant chronic pathology
  • Normal Respiratory Function Test (RFT)
  • Woman of childbearing age using an effective method of contraception

For COPD patients :

  • Diagnosis of COPD based on dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease associated with spirometry that demonstrates a post-bronchodilator FEV1/FVC ratio \< 0.70 and lack of reversibility.
  • Stage GOLD 1 (post-bronchodilator FEV1 ≥ 80% theoretical) or 2 (post-bronchodilator FEV1 between 50 and less than 80% theoretical) or 3 (post-bronchodilator FEV1 between 30 and less than 50% theoretical) For IPF patients
  • Diagnosis of idiopathic pulmonary fibrosis made less than 5 years ago on the basis of scannographic and/or histological criteria and validated at a consultation meeting on interstitial pathology according to the ATS/ERS/JRS/ALAT 2018 recommendations.

Exclusion criteria

Exclusion Criteria:

  • Recent rhino-bronchial infection (\< 6 weeks)
  • Subjects on antiplatelet or other anticoagulant medication at risk of bleeding during sampling.
  • Subjects with a history of clinically significant vaginal discomfort (i.e., recurrent or unconsciousness, etc.)
  • History of allergy or intolerance to xylocaine and/or propofol
  • History of significant epistaxis (i.e. recurrent epistaxis of any quantity or at least one severe epistaxis)
  • Subject at risk of difficult intubation according to the criteria of the 2006 FSSR expert conference*.
  • Pregnant (a urine test will be performed for all women of childbearing age) or breastfeeding woman

For patients :

  • Long-term systemic corticosteroid therapy regardless of the reason for the prescription.
  • Systemic corticosteroid therapy within the previous 3 months
  • Patient on long-term oxygen therapy
  • Chronic cardiovascular, neuro-psychic, metabolic pathology in progress, clinically significant or uncontrolled in the last 6 months
  • Other associated chronic respiratory pathology (COPD, asbestosis, bronchiectasis ...)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Interstitial pulmonary fibrosis

    Procedure: Bronchoscopy

  • Experimental
    Chronic obstructive pulmonary disease

    Procedure: Bronchoscopy

  • Experimental
    Healthy volunteers

    Procedure: Bronchoscopy

Interventions

  • ProcedureBronchoscopy

    Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)

06

What researchers measure

Primary outcomes

  1. Number of samples usable

    Time frame: 6 months

07

Study locations

1 site
  • CHU de Nice
    Nice, 06003, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04529993
Lead sponsor
Centre Hospitalier Universitaire de Nice
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Nov 18, 2020
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Mar 24, 2025

Study contacts

Sylvie LEROY, Dr
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion